Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBT (2020 - 2025)

Historic EBT for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$11.0 million.

  • Insight Molecular Diagnostics' EBT rose 1825.38% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 4110.23%. This contributed to the annual value of -$61.0 million for FY2024, which is 14284.29% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' EBT stood at -$11.0 million, which was up 1825.38% from -$9.8 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' EBT ranged from a high of $6.0 million in Q1 2023 and a low of -$35.8 million during Q4 2021
  • Over the past 5 years, Insight Molecular Diagnostics' median EBT value was -$10.3 million (recorded in 2022), while the average stood at -$11.2 million.
  • Over the last 5 years, Insight Molecular Diagnostics' EBT had its largest YoY gain of 15790.5% in 2023, and its largest YoY loss of 51092.38% in 2023.
  • Insight Molecular Diagnostics' EBT (Quarter) stood at -$35.8 million in 2021, then surged by 66.42% to -$12.0 million in 2022, then tumbled by 34.63% to -$16.2 million in 2023, then plummeted by 107.84% to -$33.6 million in 2024, then surged by 67.15% to -$11.0 million in 2025.
  • Its EBT stands at -$11.0 million for Q3 2025, versus -$9.8 million for Q2 2025 and -$6.8 million for Q1 2025.